中文 | English
Return
Total: 115 , 1/12
Show Home Prev Next End page: GO
Author:( Xiaolei HU)

2.General issues and precautions in the design for clinical trials of investigational new drugs.

Liangping HU ; Xiaolei BAO

Journal of Integrative Medicine 2011;9(2):138-42

3.Three-factor designs unable to examine the interactions (part 1).

Liangping HU ; Xiaolei BAO

Journal of Integrative Medicine 2012;10(10):1088-91

4.Three-factor designs unable to examine the interactions (part 2).

Liangping HU ; Xiaolei BAO

Journal of Integrative Medicine 2012;10(11):1229-32

5.Multifactor designs able to examine the interactions.

Xiaolei BAO ; Liangping HU

Journal of Integrative Medicine 2012;10(12):1371-4

8.The progress of thymosin ?1 and its mechanisms

Xiaolei HU ; Yunzhao ZHAO

Parenteral & Enteral Nutrition 2004;0(05):-

9.How to choose an appropriate experimental design type (Part 1).

Liangping HU ; Xiaolei BAO

Journal of Integrative Medicine 2012;10(6):615-8

10.Serologic markers in Crohn's disease

Xiaolei HU ; Yunzhao ZHAO

Journal of Medical Postgraduates 2003;0(04):-

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 115 , 1/12 Show Home Prev Next End page: GO